NCT05250661

Brief Summary

The study was carried out to determine the efficacy of propolis in the prevention of oral mucositis and gastrointestinal symptoms associated with oral mucositis in patients with leukemia, lymphoma, and myelodysplastic syndrome receiving high-dose chemotherapy and/or hematopoietic stem cell transplantation. 64 patients, 32 in the propolis and 32 in the control group, were involved in the prospective randomized controlled experimental study. While the standard oral care treatment protocol of the clinic was administered to the control group, aqueous propolis extract was applied to the propolis group in addition to the standard oral care treatment protocol.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 15, 2019

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 22, 2020

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 29, 2021

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

January 24, 2022

Completed
29 days until next milestone

First Posted

Study publicly available on registry

February 22, 2022

Completed
Last Updated

February 22, 2022

Status Verified

February 1, 2022

Enrollment Period

1.4 years

First QC Date

January 24, 2022

Last Update Submit

February 20, 2022

Conditions

Keywords

Oral MucositisPropolisHigh Dose Chemotherapy

Outcome Measures

Primary Outcomes (4)

  • Time to onset of oral mucositis

    Time to onset of oral mucositis was be evaluated by the World Health Organization Oral Toxicity Scale which record the extent and severity of oral mucositis every day. The World Health Organization Oral Toxicity Scale: range 0 to 4, Grade 0; none, Grade 1; mild, Grade 2; moderate, Grade 3; severe, Grade 4; life threatening

    For 21 days from the beginning of the chemotherapy

  • Incidence of oral mucositis

    Incidence of oral mucositis was be evaluated by the World Health Organization Oral Toxicity Scale which record the extent and severity of oral mucositis every day. The World Health Organization Oral Toxicity Scale: range 0 to 4, Grade 0; none, Grade 1; mild, Grade 2; moderate, Grade 3; severe, Grade 4; life threatening

    For 21 days from the beginning of the chemotherapy

  • Severity of oral mucositis

    Severity of oral mucositis was be evaluated by the World Health Organization Oral Toxicity Scale which record the extent and severity of oral mucositis every day. The World Health Organization Oral Toxicity Scale: range 0 to 4, Grade 0; none, Grade 1; mild, Grade 2; moderate, Grade 3; severe, Grade 4; life threatening

    For 21 days from the beginning of the chemotherapy

  • The duration of oral mucositis

    The duration of oral mucositis was be evaluated by the World Health Organization Oral Toxicity Scale which record the extent and severity of oral mucositis every day. The World Health Organization Oral Toxicity Scale: range 0 to 4, Grade 0; none, Grade 1; mild, Grade 2; moderate, Grade 3; severe, Grade 4; life threatening

    From day 1 to day 21 of chemotherapy

Secondary Outcomes (33)

  • Time to onset of at least grade 2 oral mucositis

    From day 1 to day 21 of chemotherapy

  • Time to onset of dry mouth

    From day 1 to day 21 of chemotherapy

  • Incidence of dry mouth

    For 21 days from the beginning of the chemotherapy

  • Severity of dry mouth

    For 21 days from the beginning of the chemotherapy

  • The duration of dry mouth

    For 21 days from the beginning of the chemotherapy

  • +28 more secondary outcomes

Study Arms (2)

Aqueous propolis extract

EXPERIMENTAL

The individuals in the intervention group were asked to gargle with 5 ml aqueous propolis extract four times a day after meals (morning, noon, evening and night before bedtime) and wait average one minute in the mouth and then spit, in addition to the standard practice of the clinic. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. The patients were followed for 21 days. The 21-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.

Other: Aqueous propolis extract

Control

NO INTERVENTION

Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.

Interventions

The patients gargled 4 times a day after meals and 5 ml each time. Patients were instructed to keep the propolis solution in their mouth for one minute, to touch all structures in the mouth, and not to eat or drink anything orally for one hour after spitting.

Aqueous propolis extract

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older
  • Ability to communicate verbally
  • Not having a diagnosed psychiatric disease
  • Receiving inpatient high dose chemotherapy (diagnosed with leukemia, lymphoma and MDS)
  • Hematopoietic Stem Cell Transplantation patients
  • Zero OM score according to the World Health Organization Oral Toxicity Scale (WHOOTS)
  • Karnofsky Performance Scale (KPS) score of 80 and above

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karadeniz Technical University

Trabzon, 61000, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Stomatitis

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic Diseases

Study Officials

  • Seher ÇAKMAK Karadeniz Technical University

    Karadeniz Technical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
No masking
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Parallel group, two arm, prospective randomized controlled clinical trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 24, 2022

First Posted

February 22, 2022

Study Start

May 15, 2019

Primary Completion

September 22, 2020

Study Completion

May 29, 2021

Last Updated

February 22, 2022

Record last verified: 2022-02

Locations